PATENT CLAIM ANALYSIS

Application Number: 16133322
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["424", "451000"]

Abstract:
The present invention is directed to a System characterization of NASH that combines Modeling and Biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steatohepatitis (NASH). Said conditions are Liver related complications among the array of manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of NASH and NAFLD complications in patients with hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, metabolic syndrome complications including cardiovascular diseases, neurodegenerative diseases and premature ageing, among other disease states or conditions.

Claim (Index 71):
A method for the diagnosis and treatment of non-alcohol fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) in a patient suspected of or having NAFLD and/or NASH, the method comprising obtaining a biological sample from the patient, measuring biomarkers in the biological sample which are indicative of inflammation, steatosis and/or fibrosis of the liver and other potentially affected organs of the patient and incorporating measurements of the biomarkers into a mathematical model, wherein the mathematical model computes the health of the liver and other affected organs to determine whether or not the patient requires therapy for NAFLD and/or NASH; and the patient undergoes therapy for the treatment of NAFLD and/or NASH based upon the results of the mathematical model, wherein the treatment comprises administering an effective amount of a traditional pharmacologically active agent, a composition comprising an ileal brake hormone releasing substance effective to increase the release of ileal brake hormones in said patient or a composition comprising an ileal brake hormone releasing substance effective to increase the release of ileal brake hormones in combination with a pharmacologically active agent.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 97.0
- Lexical Diversity: 1.78571
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14002642', '15162941', '15624275', '14677044', '13754855']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7230990739686008
- 35 USC 102 Novelty (BERT): 0.5656305875923738
- Combined Prediction Score: 0.7073522253309782
- Mean Citation Score: 399.312976
- Max Citation Score: 502.13965
- Similarity Product: 307.4966413695514

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test